At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.

Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).


Browse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.

Choose therapy area

Choose phase

Phase 1

A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function.

Type 1 and 2 diabetes. Phase 1.

FSI965 is a next-generation basal insulin.

OW Sema + GIP

The trial is testing the fixed ratio combination formulation of semaglutide and a once-weekly human GIP analogue

A glucose-sensitive insulin analogue intended for once-daily treatment.

A novel insulin analogue ideal for use in a closed loop pump device as delivery.

Insulin 147 & PCSK9i. Phase 1

Insulin 147 is a long-acting insulin analogue coupled via a linker to a proprietary PCSK9 inhibitory peptide for once-daily subcutaneous administration to people with diabetes in need of basal insulin and LDL cholesterol lowering

Obesity. Phase 1.

PYY 1875 is an appetite regulating hormone and is tested alone and in combination with semaglutide.

Obesity. Phase 1.

Combination of amylin (AM833) and semaglutide.

Obesity. Phase 1.

Human GDF15, is a stress-induced cytokine with multiple effects, one being appetite regulation leading to weight loss.

Sickle cell disease. Phase 1.

EPI01 is an oral combination product for treatment of sickle cell disease.

A novel monoclonal antibody intended for inhibition of ApoCIII activity. Project is developed in collaboration with STATEN.

Cardiovascular disease. Phase 1.

Subcutaneous version of PCSK9i intended to treat people with hypercholesterolaemia.

Type 2 diabetes. Phase 1

The once-weekly combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1 semaglutide.

Phase 2

Obesity. Phase 2.

A long-acting amylin analogue intended as treatment for obesity.

Macrilen. Phase 2

Trial to investigate Macrilen as a diagnosis tool for growth hormone deficiency?

A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity.

Haemophilia A. Phase 1.

Mim8 is a next-generation factor VIII mimetic bi-specific antibody for subcutaneous prophylaxis treatment of haemophilia A regardless of inhibitor status.

Phase 3

Type 1 and 2 diabetes. Phase 2.

A long-acting basal insulin analogue intended for once weekly dosing.

A long-acting oral GLP-1 analogue, 25 and 50 mg, intended for once-daily oral treatment.

Semaglutide 2.4 mg in Heart failure with preserved ejection fraction (HFpEF)

Growth disorder. Phase 3.

A long-acting human growth hormone intended to offer once-weekly injections.

NASH. Phase 2.

A long-acting GLP-1 analogue intended as once-daily treatment for non-alcoholic fatty liver disease (NASH).

Haemophilia A and B. Phase 3.

A monoclonal antibody against Tissue Factor Pathway Inhibitor (TFPI) intended for bleeding prevention after subcutaneous administration.

Semaglutide 1.0 mg in Peripheral arterial disease (PAD)?


Obesity. Phase 3.

A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity.

A long-acting GLP-1 analogue for once-weekly treatment